 |
|
|
| |
Week 48 pharmacokinetic and pharmacodynamic results of darunavir 800mg once daily when co-administered with cobicistat 150mg once daily in HIV-1-infected patients with no darunavir resistance-associated mutations: GS-US-216-0130
|
| |
| |
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, USA, May 19-21, 2014
Thomas N Kakuda,1 Anne Brochot,2 Joseph M Custodio,3 Bruce Green,4 Simon Vanveggel,5 Tom Van De Casteele,5 Magda Opsomer,5 Frank L Tomaka,1 Marshall W Fordyce,3 Richard MW Hoetelmans5
1Janssen Research & Development LLC, Titusville, NJ, USA; 2Janssen Research & Development, Beerse, Belgium; 3Gilead Sciences, Foster City, CA, USA; 4Model Answers Pty Ltd, Brisbane, Australia; 5Janssen Infectious Diseases BVBA, Beerse, Belgium
|
| |
|
|
|
|
|
